Dose-Dependent Survival and Solid Lung Responses: BioNTech’s ASCO Data in Focus
01.06.2026 - 16:32:26 | boerse-global.de
BioNTech used this year’s ASCO meeting in Chicago to reinforce its oncology ambitions, but the data it unveiled came with a dose of complexity. The German biotech presented results across two tumour types – ovarian and lung cancer – each offering a different kind of signal for a company still wrestling with the transition away from pandemic-era revenue.
For ovarian cancer, the focus fell on Gotistobart, a CTLA-4-targeting candidate developed with OncoC4. Interim analysis from the Phase?2 PRESERVE-004 study, which paired Gotistobart with pembrolizumab in heavily pretreated patients, produced a notable split: the lower 1?mg/kg dose delivered a median overall survival of 18.9 months, while the higher 2?mg/kg dose yielded only 8.3 months. That divergence places the programme in a delicate spot.
Progression-free survival was less stark – 2.2 months for the low dose versus 2.5 months for the high – and the confirmed response rate came in at 21% across both arms. The 62 evaluable patients had received a median of four prior lines of therapy, with some having undergone as many as ten, underscoring the refractory nature of the group.
Tolerability also varied by dose. Gotistobart-related dose interruptions affected 33% of patients in the lower arm and 38% in the higher arm; treatment discontinuation rates were 15% and 31%, respectively. One treatment-related death from cardiac arrest occurred in the low-dose cohort. BioNTech characterised the overall safety profile as manageable, but the asymmetry between dose and efficacy remains a puzzle the company will need to solve before any pivotal plans for ovarian cancer are laid out. To date, no such plans have been announced for that indication.
Should investors sell immediately? Or is it worth buying BioNTech?
Lung cancer, in contrast, offered a clearer momentum. BioNTech and partner Bristol Myers Squibb presented interim data from the global Phase?2 ROSETTA Lung?02 study evaluating Pumitamig – a bispecific antibody blocking PD-L1 and VEGF-A – in combination with chemotherapy as a first-line treatment for advanced non-small cell lung cancer. The confirmed objective response rate reached 63.6% in the non?squamous cohort and jumped to 72.7% in the squamous cohort, based on 40 evaluable patients with a median follow?up of 9.0 months.
Pumitamig is the first PD-(L)1×VEGF bispecific to generate global first-line data, and the Phase?3 portion of the study is already under way. That puts BioNTech in a competitive space where rival programmes are advancing quickly. During the same ASCO session, Summit Therapeutics presented Phase?3 results for ivonescimab from the HARMONi?6 study, showing a median overall survival of 27.9 months versus 23.7 months for tislelizumab in advanced squamous NSCLC – a reminder of the bar Pumitamig will eventually have to meet.
Shortly before ASCO, UBS lifted its stance on BioNTech from “Neutral” to “Buy” and raised the price target from $117 to $135. The upgrade explicitly cited the broadening oncology pipeline as the key valuation driver beyond the COVID?19 vaccine business. The analyst note aligns with the strategic narrative BioNTech is trying to build: that its late?stage research can generate meaningful commercial assets.
Still, the financial reality keeps the stock in a transitional phase. For the first quarter of 2026, BioNTech reported revenue of €118.1 million and a net loss of €531.9 million, or a loss per share of €2.10. (In dollar terms, the company reported $118.1 million in revenue and a net loss of $494.6 million.) Heavy investment in a pipeline that now encompasses more than 25 Phase?2 and Phase?3 studies, including 13 registrational trials, is the main driver of the red ink. The programmes cover immunomodulators, antibody-drug conjugates and mRNA?based cancer therapies.
BioNTech at a turning point? This analysis reveals what investors need to know now.
The clinical calendar will dictate the next phase of the story. In non?small cell lung cancer, the ongoing Phase?3 Pumitamig study provides the next hard data anchor. For ovarian cancer, the Gotistobart data, while biologically interesting, lack a committed next step. BioNTech also has Phase?3 studies under way in breast cancer and a Phase?2 mpox vaccine trial, giving the pipeline breadth but also raising the execution bar.
The stock itself reflects the wait?and?see mood. On Monday, BioNTech shares traded at €81.60, down 0.91% on the day, while on a weekly basis they were up 3.38% at €82.50. Over twelve months the stock remains 16.58% lower – a gap BioNTech hopes to close with the next wave of clinical readouts.
Ad
BioNTech Stock: New Analysis - 1 June
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
